소아청소년기 당뇨병성 신병증 (II) ; 병리 소견 및 병태생리를 중심으로

키워드

참고문헌 (148)

1. US Renal Data System, "USRDS 2008 Annual Data Report" (2007), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2007
2. Stengel B, "Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe", Dial Transplant, 18, pp.1824~1833 (2003)
3. ESRD Registry Committee, "Current renal replacement therapy in Korea", Korean J Nephrol, 26, pp.459~481 (2007)
4. 하태선, "소아청소년기 당뇨병성 신병증(I); 임상 소견을 중심으로", 대한소아신장학회지, 13(1), pp.1~13 (2009), 대한소아신장학회
5. Taft JL, "A clinical-histological study of individuals with diabetes mellitus and proteinuria", Diabet Med, 7, pp.215~221 (1990)
6. Parving H-H, "Diabetic nephropathy. In: The Kidney", pp.1265~1298 (2008), WB Saunders
7. Mauer SM, "The development of lesions in the glomerular basement membrane and mesangium after transplantation of normal kidneys to diabetic patients", Diabetes, 32, pp.948~952 (1983)
8. Mauer SM, "Structural-functional relationships in diabetic nephropathy", J Clin Invest, 74, pp.1143~1155 (1984)
9. Hayashi H, "An electron microscopic study of glomeruli in Japanese patients with non-insulin dependent diabetes mellitus", Kidney Int, 41, pp.749~757 (1992)
10. Østerby R, "Morphometric studies of the peripheral glomerular basement membrane in early juvenile diabetes. I. Development of initial basement membrane thickening", Diabetologia, 8, pp.84~92 (1972)
11. Østerby R, "Early phases in the development of diabetic glomerulopathy", Acta Med Scand Suppl, 574, pp.3~82 (1974)
12. O'Connor AS, "Diabetes and the kidney", Am J Kidney Dis, 46, pp.766~773 (2005)
13. Fioretto P, "Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria", Diabetes, 43, pp.1358~1364 (1994)
14. Fioretto P, "Histopathology of diabetic nephropathy", Semin Nephrol, 27, pp.195~207 (2007)
15. Nishi S, "Ultrastructural characteristics of diabetic nephropathy", Med Electron Microsc, 33, pp.65~73 (2000)
16. Kimmelstiel P, "Intercapillary lesions in glomeruli of kidney", Am J Pathol, 12, pp.83~97 (1936)
17. Glick AD, "Mesangial deposition of type I collagen in human glomerulosclerosis", Hum Pathol, 23, pp.1373~1379 (1992)
18. Makino H, "Localization of fibril", microfibril and basement membrane collagens in diabetic glomerulosclerosis in type 2 diabetes, 1994, pp.11, 304~311
19. Imai N, "Histological localization of advanced glycosylation end products in the progression of diabetic nephropathy", Nephron, 76, pp.153~160 (1997)
20. Shioi A, "Disorganization process in the development of diabetic nodular glomerulosclerosis", Tohoku J Exp Med, 159, pp.257~275 (1989)
21. Murussi M, "Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study", Diabetes Care, 25, pp.1101~1103 (2002)
22. Mazzucco G, "Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies", Am J Kidney Dis, 39, pp.713~720 (2002)
23. Hong D, "Nodular glomerular lesion: a later stage of diabetic nephropathy?", Diabetes Res Clin Pract, 78, pp.189~195 (2007)
24. Ueno M, "Diabetic capsular drop, fibrin cap, and the other exudative lesions (in Japanese)", Nippon Rinsho Suppl, 17, pp.213~216 (1997)
25. Farquhar MG, "Diabetic glomerulosclerosis: electron and light microscopic studies", Am J Pathol, 35, pp.721~735 (1959)
26. Bader R, "Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters", Pathol Res Pract, 167, pp.204~216 (1980)
27. Giordano C, "The genesis of the Armanni-Ebstein lesion in diabetic nephropathy", J Diabet Complications, 1, pp.2~3 (1987)
28. Kaneda K, "Mitochondrial enlargement and basement membrane thickening of renal proximal tubules, possible initiators of microalbuminuria in non-insulindependent diabetics (NIDDM)", Acta Pathol Jpn, 42, pp.793~799 (1992)
29. Ditscherlein G, "Renal histopathology in hypertensive diabetic patients", Hypertension, 7, pp.1129~1132 (1985)
30. Boeri D, "Intrarenal arteriosclerosis and impairment of kidney function in NIDDM subjects", Diabetologia, 41, pp.121~124 (1998)
31. Cooper ME, "Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy", Diabetologia, 44, pp.1957~1972 (2001)
32. Zatz R, "Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension", J Clin Invest, 77, pp.1925~1930 (1986)
33. Brownlee M, "Biochemistry and molecular cell biology of diabetic complications", Nature, 414, pp.813~820 (2001)
34. Brownlee M, "The pathobiology of diabetic complications: a unifying mechanism", Diabetes, 54, pp.1615~1625 (2005)
35. Higgins PJ, "Kinetic analysis of nonenyzmatic glycosylation of hemoglobin", J Biol Chem, 256, pp.5204~5208 (1981)
36. Vlassara H, "Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging", Lab Invest, 70, pp.138~151 (1994)
37. Makino H, "Roles of advanced glycation end-products in the progression of diabetic nephropathy", Nephrol Dial Transplant, 11(5), pp.76~80 (1996)
38. Greene DA, "Sorbitol, phosphoinositides, and sodium-potassium- ATPase in the pathogenesis of diabetic complications", N Engl J Med, 316, pp.599~606 (1987)
39. Dunlop M, "Aldose reductase and the role of the polyol pathway in diabetic nephropathy", Kidney Int, (77), pp.S3~S12 (2000)
40. Passariello N, "Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular fitration rate in IDDM subjects with nephropathy", Diabetes Care, 16, pp.789~795 (1993)
41. Srivastava SK, "Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options", Endocr Rev, 26, pp.380~392 (2005)
42. Srinivasan V, "Glutamine fructose-6-phosphate amidotransferase (GFAT) gene expression and activity in patients with type 2 diabetes: inter-relationships with hyperglycaemia and oxidative stress", Clin Biochem, 40, pp.952~957 (2007)
43. Cooksey RC, "Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione", Endocrinology, 140, pp.1151~1157 (1999)
44. Bohlender JM, "Advanced glycation end products and the kidney", Am J Physiol Renal Physiol, 289, pp.F645~F659 (2005)
45. McRobert EA, "The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications", J Biol Chem, 278, pp.25783~25789 (2003)
46. Goldin A, "Advanced glycation end products: sparking the development of diabetic vascular injury", Circulation, 114, pp.597~605 (2006)
47. Schiekofer S, "Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42", 44MAPK, and nuclear factor κB in PBMCs, 2003, pp.52, 621~633
48. Yan SD, "Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors", binding proteins, 1994, pp.269, 9889~9897
49. Silbiger S, "Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge", Kidney Int, 43, pp.853~864 (1993)
50. Mott JD, "Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility", Kidney Int, 52, pp.1302~1312 (1997)
51. Throckmorton DC, "PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products", Kidney Int, 48, pp.111~117 (1995)
52. Forbes JM, "Role of advanced glycation end products in diabetic nephropathy", J Am Soc Nephrol, 14(3), pp.S254~S258 (2003)
53. Makita Z, "Advanced glycosylation end products in patients with diabetic nephropathy", N Engl J Med, 325, pp.836~842 (1991)
54. Soulis-Liparota, "Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fIuorescence in streptozocin-induced diabetic rat", Diabetes, 40, pp.1328~1334 (1991)
55. Vlassara H, "Advanced glycosylation endproducts induce glomerular sclerosis and albuminuria in normal rats", Proc Natl Acad Sci USA, 91, pp.11704~11718 (1994)
56. Yang CW, "Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis", Kidney Int, 47(49), pp.S55~S58 (1995)
57. Striker LJ, "Administration of AGEs in vivo induces extracellular matrix gene expression", Nephrol Dial Transplant, 11(5), pp.62~65 (1996)
58. Ha T-S, "Researches on the pathophysiology of proteinuria in diabetic nephropathy", Korean J Pediatr, 41(1), pp.S69~S74 (1998)
59. Hovind P, "Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study", BMJ, 328, pp.1105~1109 (2004)
60. Parving H-H, "Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy", Lancet, 1, pp.1175~1179 (1983)
61. Mogensen CE, "Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes", J Intern Med, 254, pp.45~66 (2003)
62. Wolf G, "New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology", Eur J Clin Invest, 34, pp.785~796 (2004)
63. Giunti S, "Mechanisms of diabetic nephropathy: role of hypertension", Hypertension, 48, pp.519~526 (2006)
64. Hostetter TH, "Hyperfiltration and glomerulosclerosis", Semin Nephrol, 23, pp.194~199 (2003)
65. Harris RC, "Continuous stretch-relaxation in culture alters rat mesangial cell morphology, growth characteristics, and metabolic activity", Lab Invest, 66, pp.548~554 (1992)
66. Cortes P, "Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy", Kidney Int, 51, pp.57~68 (1997)
67. Gruden G, "Mechanical stretch induces vascular permeability factor in human mesangial cells: Mechanisms of signal transduction", Proc Natl Acad Sci USA, 94, pp.12112~12116 (1997)
68. Sugimoto H, "Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation", Diabetes, 46, pp.2075~2081 (1997)
69. Petermann AT, "Mechanical stress reduces podocyte proliferation in vitro", 61, pp.40~50 (2002)
70. Kriz W, "A role for podocytes to counteract capillary wall distension", Kidney Int, 45, pp.369~376 (1994)
71. Endlich N, "Podocytes respond to mechanical stress in vitro", J Am Soc Nephrol, 12, pp.413~422 (2001)
72. Dessapt C, "Mechanical forces and TGFβ1 reduce podocyte adhesion through α3β1 integrin downregulation", Nephrol Dial Transplant, 24, pp.2645~2655 (2009)
73. Johnson RJ, "Renal injury from angiotensin II mediated hypertension", Hypertension, 19, pp.464~474 (1992)
74. Anderson S, "Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat", Miner Electrolyte Metab, 24, pp.406~411 (1998)
75. Klahr S, "Angiotensin II and gene expression in the kidney", Am J Kidney Dis, 31, pp.171~176 (1998)
76. Haugen EN, "Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro", Kidney Int, 58, pp.144~152 (2000)
77. Cooper ME, "Diabetic vascular complications", Clin Exp Pharmacol Physiol, 24, pp.770~775 (1997)
78. Cooper ME, "Renal protection and ACE inhibition in microalbuminuric type I and type II diabetic patients", J Hypertens, 14, pp.S11~S14 (1996)
79. ACE Inhibitors in Diabetic Nephropathy Trialist Group, "Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta- analysis of individual patient data", Ann Intern Med, 134, pp.370~379 (2001)
80. Brenner BM, "RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", N Engl J Med, 345, pp.861~869 (2001)
81. Sarafidis PA, "Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis", Am J Hypertens, 21, pp.922~929 (2008)
82. Zatz R, "Prevention of diabetic glomerulapathy by pharmacological amelioration of glomerular capillary hypertension", J Clin Invest, 77, pp.1925~1930 (1986)
83. Gilbert RE, "Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition", Diabetes, 47, pp.414~422 (1998)
84. Nguyen G, "Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents", Exp Physiol, 93, pp.557~563 (2008)
85. Danser AH, "Novel drugs targeting hypertension: renin inhibitors", J Cardiovasc Pharmacol, 50, pp.105~111 (2007)
86. Ichihara A, "Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin", J Clin Invest, 114, pp.1128~1135 (2004)
87. Luetscher JA, "Increased plasma inactive renin in diabetes mellitus. A marker of micro-vascular complications", N Engl J Med, 312, pp.1412~1417 (1985)
88. Deinum J, "Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus", Diabetologia, 42, pp.1006~1010 (1999)
89. Parving HH, "AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy", N Engl J Med, 358, pp.2433~2446 (2008)
90. Persson F, "Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes", Kidney Int, 73, pp.1419~1425 (2008)
91. Sun Y, "Aldosterone-induced inflammation in the rat heart : role of oxidative stress", Am J Pathol, 161, pp.1773~1781 (2002)
92. Greene EL, "Role of aldosterone in the remnant kidney model in the rat", J Clin Invest, 98, pp.1063~1068 (1996)
93. Fujisawa G, "Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats", Kidney Int, 66, pp.1493~1502 (2004)
94. Han SY, "Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats", J Am Soc Nephrol, 17, pp.1362~1372 (2006)
95. Schjoedt KJ, "Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy", Kidney Int, 70, pp.536~542 (2006)
96. Sato A, "Effectiveness of aldosterone blockade in patients with diabetic nephropathy", Hypertension, 41, pp.64~68 (2003)
97. Kang YS, "Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats", Nephrol Dial Transplant, 24, pp.73~84 (2009)
98. Joffe HV, "Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus", J Clin Endocrinol Metab, 92, pp.2552~2558 (2007)
99. Nishizuka Y, "Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C", Science, 258, pp.607~614 (1992)
100. Koya D, "Protein kinase C activation and the development of diabetic complications", Diabetes, 47, pp.859~866 (1998)
101. Koya D, "Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats", J Clin Invest, 100, pp.115~126 (1997)
102. Haneda M, "Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions", Diabetes, 46, pp.847~853 (1997)
103. Ruan X, "Role of protein kinase C in angiotensin II-induced renal vasoconstrictin in genetically hypertensive rats", Am J Physiol, 270, pp.F945~F952 (1996)
104. Perico N, "Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats", Diabetes, 41, pp.533~538 (1992)
105. Sharma K, "Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediatio via protein kinase C", Biochem Biophys Res Commun, 207, pp.80~88 (1995)
106. Ishii H, "Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor", Science, 272, pp.728~731 (1996)
107. Babazono T, "Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells", Diabetes, 47, pp.668~676 (1998)
108. Del Prete D, "Molecular biology of diabetic gloomerulosclerosis", Nephrol Dial Transplant, 13(8), pp.20~25 (1998)
109. White MF, "The insulin signalling system and the IRS proteins", Diabetologia, 40, pp.S2~S17 (1997)
110. Ueki K, "Potential role of protein kinase B in insulin- induced glucose transport, glycogen synthesis, and protein synthesis", J Biol Chem, 273, pp.5315~5322 (1998)
111. Vanhasebroeck B, "The PI3K-PDK1 connection: more than just a road to PKB", Biochem J, 346, pp.561~576 (2000)
112. Datta SR, "Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery", Cell, 91, pp.231~241 (1997)
113. Konishi H, "Activation of RAC-protein kinase by heat shock and hyperosmolarity stress through a pathway independent of phosphatidylinositol 3-kinase", Proc Natl Acad Sci USA, 93, pp.7639~7643 (1996)
114. Kohn AD, "Expression of a constitutively active Akt Ser", Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation, 1996, pp.271, 31372~31378
115. Bhandari T, "Insulin regulation of protein translation repressor 4E-BP1, an elF4E binding protein, in renal epithelial cells involves diverse signaling pathways", Kidney Int, 59, pp.866~875 (2001)
116. Kyriakis JM, "Mammalian mitogen- activated protein kinase signal transduction pathways activated by stress and inflammation", Physiol Rev, 81, pp.807~869 (2001)
117. Hsieh TJ, "High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells", Endocrinology, 143, pp.2975~2985 (2002)
118. Ishida T, "Stretch-induced overexpression of fibronectin in mesangial cells is mediated by the activation of mitogen-activated protein kinase", Diabetes, 48, pp.595~602 (1999)
119. Nose A, "Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: Involvement of HB-EGF and EGF receptor transactivation", Hypertens Res, 26, pp.67~73 (2003)
120. Toyoda M, "High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy", Kidney Int, 66, pp.1107~1114 (2004)
121. Sakai N, "Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy", Am J Kidney Dis, 45, pp.54~65 (2005)
122. Sharma K, "Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy", Semin Nephrol, 17, pp.80~92 (1997)
123. Peters H, "Transforming growth factor-beta in human glomerular injury", Curr Opin Nephrol Hypertens, 6, pp.389~393 (1997)
124. Fumo P, "PKC and high glucose stimulate collagen alpha 1 (IV) transcriptional activity in a reporter mesangial cell line", Am J Physiol, 267, pp.632~638 (1994)
125. Nakamura T, "mRNA expression of growth factors in glomeruli from diabetic rats", Diabetes, 42, pp.450~456 (1993)
126. Sharma K, "Neutralization of TGF β antibody attenuates kidney hypertrophy and the enhanced extracelluar matrix gene expression in STZ-induced diabetic mice", Diabetes, 45, pp.522~530 (1996)
127. Ferrara N, "The biology of VEGF and its receptors", Nat Med, 9, pp.669~676 (2003)
128. Schrijvers BF, "The role of vascular endothelial growth factor (VEGF) in renal pathophysiology", Kidney Int, 65, pp.2003~2017 (2004)
129. Cooper ME, "Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes", Diabetes, 48, pp.2229~2239 (1999)
130. Lee EY, "Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes", Nephrol Dial Transplant, 21, pp.1496~1503 (2006)
131. Shulman K, "Expression of vascular permeability factor (VPF", VEGF) is altered in many glomerular diseases, 1996, pp.7, 661~666
132. de Vriese AS, "Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes", J Am Soc Nephrol, 12, pp.993~1000 (2001)
133. Flyvbjerg A, "Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody", Diabetes, 51, pp.3090~3094 (2002)
134. Schrijvers BF, "A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat", Nephrol Dial Transplant, 21, pp.324~329 (2006)
135. 이은영, "Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes", Experimental and Molecular Medicine, 36(1), pp.65~70 (2004), 생화학분자생물학회
136. Tsuchida K, "Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195", Diabetologia, 42, pp.579~588 (1999)
137. Tesch GH, "MCP-1", CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy, 2008, pp.294, F697~F701
138. Fornoni A, "Role of inflammation in diabetic nephropathy", Curr Diabetes Rev, 4, pp.10~17 (2008)
139. Navarro-Gonzalez JF, "The role of inflammatory cytokines in diabetic nephropathy", J Am Soc Nephrol, 19, pp.433~442 (2008)
140. Chow FY, "Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice", Kidney Int, 69, pp.73~80 (2006)
141. Giunti S, "Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes, and in vitro in human mesangial cells", Diabetologia, 51, pp.198~207 (2008)
142. Gu L, "Pravastatin inhibits carboxymethyllysine-induced monocyte chemoattractant protein 1 expression in podocytes via prevention of signaling events", Nephron Exp Nephrol, 106, pp.e1~e10 (2007)
143. Lee EY, "The monocyte chemoattractant protein-1", CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability, 2009, pp.297, F85~F94
144. Tan AL, "AGE, RAGE, and ROS in diabetic nephropathy", Semin Nephrol, 27, pp.130~143 (2007)
145. Ha H, "Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney", Nephrology (Carlton), (10), pp.S7~S10 (2005)
146. Susztak K, "Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy", Diabetes, 55, pp.225~233 (2006)
147. Forbes JM, "Oxidative stress as a major culprit in kidney disease in diabetes", Diabetes, 57, pp.1446~1454 (2008)
148. Ha T-S, "Effects of advanced glycation endproducts on rat glomerular epithelial cells:Roles of reactive oxygen species", Korean J Nephrol, 22, pp.285~293 (2003)